Novotech partners with major hospitals to strengthen South Korean clinical capabilities

Novotech CEO Dr John Moller said increasingly biotech clients were running their Phase I studies in Australia and benefiting from the 41% R&D tax credit, then moving into Asia for the next phases.

New Delhi: Novotech, a regional full-service contract research organization (CRO) has strengthened its presence in South Korea with two major hospitals joining the Novotech partnership program, bringing more quality investigators, KOLs, and up to 4 million patients.

The 900 bed Ulsan University Hospital (UUH) and the Hepatology Division in Gastroenterology, Department of Internal Medicine, part of the 1,778 bed Seoul National University Hospital (SNUH), are now in the Novotech CRO partnership program, further strengthening Novotech’s clinical service capabilities in South Korea.

South Korea is a fast-growing destination for clinical studies with quality infrastructure, world-class medical and hospital facilities, as well as supportive rapid start-up regulations. Last year, South Korea has been the most active country in clinical research in Asia after China, with over 400 sites opened by biopharma companies.

Novotech CEO Dr John Moller said increasingly biotech clients were running their Phase I studies in Australia and benefiting from the 41% R&D tax credit, then moving into Asia for the next phases.

“Having the same company that knows and understands the study as it transitions into Asia is always reassuring for clients. Novotech off course uses the very latest in Oracle and Medidata technology, so seamlessly connects with global clinical partners.”

Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of phase I - IV clinical trials across the Asia Pacific region.

Also Read: AstraZeneca, Merck, Myriad expands companion diagnostic partnership